Alcidion Group

Alcidion Group Equity Ratio

The Equity Ratio of Alcidion Group (ALC.AX) as of Nov 11, 2026 is 74.56 %. In the previous year, Equity Ratio was 75.94 % — a change of -1.82% (lower).

Equity Ratio

74.56 %

YoY

-1.82%

Last updated:

Equity Ratio of Alcidion Group is 2026 74.56 % . Equity Ratio of Alcidion Group was 2025 75.94 % . It decreases by -1.82% lower compared to the previous year.

The Alcidion Group Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
53.27 AUD
Jan 1, 2020
75.41 AUD
Jan 1, 2021
77.45 AUD
Jan 1, 2022
73.20 AUD
Jan 1, 2023
74.71 AUD
Jan 1, 2024
75.96 AUD
Jan 1, 2025
75.94 AUD
Jan 1, 2026
74.56 AUD
The Alcidion Group Equity Ratio history
YEAREquity RatioYoY
74.56 %-1.82%
75.94 %-0.03%
75.96 %+1.67%
74.71 %+2.07%
73.20 %-5.49%
77.45 %+2.71%
75.41 %+41.55%
53.27 %-6.81%
57.17 %-27.98%
79.38 %-2.60%
81.49 %-18.18%
99.61 %-0.04%
99.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alcidion Group Stock analysis

What does Alcidion Group do? Alcidion Group Ltd. generates revenue through the development and licensing of its healthcare software products, including Miya Precision, Miya Observations, Flow, Task Management, and PAS, marketed under the Miya brand. The company also resells selected healthcare software from strategic partners and provides implementation, support, maintenance, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its flagship product Miya Precision, a FHIR-event platform-based solution, supports clinical and operational applications, while Smartpage offers hospital communication and task management via smartphone and web. The firm serves over 400 hospitals across its key markets. Miya Precision and its associated modules form the core of Alcidion's product portfolio, targeting hospitals seeking integrated clinical solutions. Smartpage, Patientrack, and Silverlink PCS complement these offerings, catering to diverse healthcare communication and operational needs. The company’s revenue streams are driven by direct sales of software licenses, ongoing service contracts, and partner resales, with a focus on the Australian, New Zealand, and UK healthcare sectors. Alcidion’s business model emphasizes software licensing and service delivery, with Miya Precision as the primary revenue generator. The company’s strategic partnerships enable it to resell third-party software, expanding its product range without additional development costs. Healthcare institutions in Australia, New Zealand, and the United Kingdom are the primary buyers, leveraging Alcidion’s solutions for improved clinical workflows and operational efficiency. Alcidion Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alcidion Group stock

Equity Ratio of Alcidion Group is 74.56 % in 2026.

Equity Ratio of Alcidion Group changed from 75.94 % to 74.56 %, representing a -1.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Alcidion Group since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Alcidion Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Alcidion Group

All Key Metrics — Alcidion Group